Year 2026 / Volume 118 / Number 1
Editorial
Pancreatic neuroendocrine tumors — Bridging knowledge gaps for better outcomes

1-4

DOI: 10.17235/reed.2025.11255/2025

Diana Fresneda Cuesta, José Díaz Tasende,

Abstract
Clinical decision-making in patients with pancreatic neuroendocrine tumors is complex. The absence of effective biomarkers and the reliance on morphological criteria underlying current predictive models expose patients to a substantial risk of overdiagnosis and overtreatment. The implementation of non-invasive tools that improve the precision of prognostic estimates remains an unmet clinical need.
New comment
Comments
No comments for this article
References
1 Mohindroo C, Baydogan S, Agarwal P, et al. Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors. Cancer Prev Res (Phila). 2024;17:335-342. doi:10.1158/1940-6207.
2 Yang Z, Shi G. Comparative outcomes of pancreatic neuroendocrine neoplasms: A population-based analysis of the SEER database. Eur J Surg Oncol. 2022;48(10):2181-2187. doi:10.1016/j.ejso.2022.05.016.
3 Rindi G, Klimstra DS, Abedi-Ardekani B, et al: A common classification framework for neuroendocrine neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018; 31:1770-1786. doi: 10.1038/s41379-018-0110-y.
4 Kos-Kudła B, Castaño JP, Denecke T, et al. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol. 2023;35:e13343. doi: 10.1111/jne.13343.
5 Howe JR, Merchant NB, Conrad C, et al: The North American Neuroendocrine Tumor Society Consensus Paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 49:1-33, 2020.
6 National Comprehensive Cancer Network. Neuroendocrine and Adrenal Tumors (Version 5.2024). https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed February 10, 2025.
(Version 5.2024 ). https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed February 10, 2025.
7 van Beek DJ, Takkenkamp TJ, Wong-Lun-Hing EM, et al. Risk factors for complications after surgery for pancreatic neuroendocrine tumors. Surgery. 2022;172(1):127-136. doi:10.1016/j.surg.2022.02.007.
8 Partelli S, Massironi S, Zerbi A, et al. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial. Br J Surg. 2022;109(12):1186-1190. doi:10.1093/bjs/znac267
9 Tanaka M, Heckler M, Mihaljevic AL, et al. Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2021;28(3):1614-1624. doi:10.1245/s10434-020-08850-7.
10 Assi HA, Mukherjje S, Kunz PL et al: Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database The Oncologist 2020; 25:e276–e283 .
11 Heidsma CM, Tsilimigras DI, Rocha F, et al. Clinical relevance of performing endoscopic ultrasound-guided fine-needle biopsy for pancreatic neuroendocrine tumors less than 2 cm. J Surg Oncol. 2020;122(7):1393-1400. doi:10.1002/jso.26158.
12 Tacelli M, Bina N, Crinò SF, et al. Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data. Gastrointest Endosc. 2022 ;96(6):898-908.e23. doi: 10.1016/j.gie.2022.07.014. Epub 2022 Jul 19. PMID: 35863518.
13 Nguyen M, Li M, Travers A, Segelov E. Role of Chromogranin A in the Diagnosis and Follow-up of Neuroendocrine Tumors: Real-World Experience. Pancreas. 2022;51(8):1007-1010. doi:10.1097/MPA.0000000000002132.
14 Partelli S, Muffatti F, Andreasi V, et al. A Single-center Prospective Observational Study Investigating the Accuracy of Preoperative Diagnostic Procedures in the Assessment of Lymph Node Metastases in Nonfunctioning Pancreatic Neuroendocrine Tumors. Ann Surg. 2022;276(5):921-928. doi:10.1097/SLA.0000000000005615.
15 Heidsma CM, Engelsman AF, van Dieren S, et al. Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA). Br J Surg. 2021;108:888-891. doi: 10.1093/bjs/znab088. PMID: 33783475; PMCID: PMC10364894.
16 Kim JY, Brosnan-Cashman JA, An S, et al. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. Clin Cancer Res. 2017;23(6):1598-1606. doi:10.1158/1078-0432.CCR-16-1147.
17 Öberg K, Califano A, Strosberg JR, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol. 2020;31(2):202-212. doi:10.1016/j.annonc.2019.11.003.
18 Bodei L, Kidd MS, Singh A, et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging. 2020;47(4):895-906. doi:10.1007/s00259-019-04601-3
19 Homps M, Soyer P, Coriat R, et al. A preoperative computed tomography radiomics model to predict disease-free survival in patients with pancreatic neuroendocrine tumors. Eur J Endocrinol. 2023;189(4):476-484. doi:10.1093/ejendo/lvad130.
20 Ma M, Gu W, Liang Y, et al. A novel model for predicting postoperative liver metastasis in R0 resected pancreatic neuroendocrine tumors: integrating computational pathology and deep learning-radiomics. J Transl Med. 2024;22(1):768. Published 2024 Aug 14. doi:10.1186/s12967-024-05449-4.
Related articles

Review

New non-invasive biomarkers for colorectal cancer screening

DOI: 10.17235/reed.2020.7233/2020

Letter to the Editor

Author´s reply: Cystic pancreatic neuroendocrine tumors. A diagnostic challenge

DOI: 10.17235/reed.2018.5415/2017

Letter to the Editor

Neuroendocrine tumors of the pancreas: keys issues in dealing with heterogeneity

DOI: 10.17235/reed.2017.4997/2017

Letter to the Editor

Pancreatic neuroendocrine tumors

DOI: 10.17235/reed.2017.4725/2016

Citation tools
Fresneda Cuesta D, Díaz Tasende J. Pancreatic neuroendocrine tumors — Bridging knowledge gaps for better outcomes. 11255/2025


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 6 visits.
This article has been downloaded 0 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 02/04/2025

Accepted: 22/04/2025

Online First: 18/12/2025

Published: 14/01/2026

Article Online First time: 260 days

Article editing time: 287 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2026 y Creative Commons. The Spanish Journal of Gastroenterology